Patents by Inventor Loes Van Schie

Loes Van Schie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SARBECOVIRUS BINDERS
    Publication number: 20240101647
    Abstract: Agents that bind to sarbecoviruses of multiple clades, neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Applications and uses of these agents are further disclosed.
    Type: Application
    Filed: February 7, 2022
    Publication date: March 28, 2024
    Inventors: Xavier SAELENS, Dorien DE VLIEGER, Iebe ROSSEY, Sieglinde DE CAE, Koen SEDEYN, Loes VAN SCHIE, Hannah EECKHAUT, Daria FIJALKOWSKA, Catelijne STORTELERS, Bert SCHEPENS, Nico CALLEWAERT, Han REMAUT, Wim NERINCKX, Kenny ROOSE, Dirk REITER
  • Glycosylation of variable immunoglobulin domains
    Patent number: 11891451
    Abstract: The present invention provides nucleotide sequences encoding polypeptides comprising immunoglobulin variable domains with engineered glycosylation acceptor sites. Specifically, the invention provides immunoglobulin variable domain proteins modified with selected glycans and specific glycan-conjugates thereof. Also provided herein are methods for the production of glycosylated immunoglobulin variable domains and glycan-conjugates thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 6, 2024
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Nico Callewaert, Bram Laukens, Loes Van Schie, Wander Van Breedam, Wim Nerinckx
  • CORONA VIRUS BINDERS
    Publication number: 20230227537
    Abstract: The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses.
    Type: Application
    Filed: February 5, 2021
    Publication date: July 20, 2023
    Inventors: Bert SCHEPENS, Xavier SAELENS, Nico CALLEWAERT, Dorien DE VLIEGER, Loes VAN SCHIE, Wim NERINCKX, Kenny ROOSE, Wander VAN BREEDAM, Hannah EECKHAUT, Daria FIJALKOWSKA, Chiara LONIGRO, Sieglinde DE CAE, Bruno DOMBRECHT, Catelijne STORTELERS, Johan NEYTS, Leen DELANG, Suzanne KAPTEIN, Joana DUARTE DA ROCHA PEREIRA, Barney GRAHAM, Jason MCLELLAN, Daniel WRAPP, Han REMAUT
  • Glycosylated Single Chain Immunoglobulin Domains
    Publication number: 20230062229
    Abstract: The present application relates to glycosylated immunoglobulin domains. The invention provides nucleotide sequences encoding polypeptides comprising immunoglobulin variable domains with engineered glycosylation acceptor sites. Accordingly, the invention provides immunoglobulin variable domain proteins modified with selected glycans and specific glycan-conjugates thereof. Also provided herein are methods for the production of glycosylated immunoglobulin variable domains and glycan-conjugates thereof.
    Type: Application
    Filed: December 10, 2020
    Publication date: March 2, 2023
    Inventors: Nico Callewaert, Loes Van Schie, Wander Van Breedam
  • Compositions for use to treat cataract
    Patent number: 11478499
    Abstract: A non-surgical treatment of cataract in a human or animal. The invention specifically relates to the administration of a deglycating enzyme and its cofactor(s), which results in the deglycation of the lens crystallins. The disclosure thus relates to a minimal invasive type of treatment of cataract, which is easier and cheaper compared to existing surgical methods.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 25, 2022
    Assignees: Universiteit Gent, VIB VZW
    Inventors: Elisabeth Van Aken, Joris Delanghe, Nico Callewaert, Loes Van Schie
  • COMPOSITIONS FOR USE TO TREAT CATARACT
    Publication number: 20210030780
    Abstract: A non-surgical treatment of cataract in a human or animal. The invention specifically relates to the administration of a deglycating enzyme and its cofactor(s), which results in the deglycation of the lens crystallins. The disclosure thus relates to a minimal invasive type of treatment of cataract, which is easier and cheaper compared to existing surgical methods.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 4, 2021
    Inventors: Elisabeth Van Aken, Joris Delanghe, Nico Callewaert, Loes Van Schie
  • GLYCOSYLATION OF VARIABLE IMMUNOGLOBULIN DOMAINS
    Publication number: 20200148790
    Abstract: The present invention provides nucleotide sequences encoding polypeptides comprising immunoglobulin variable domains with engineered glycosylation acceptor sites. Specifically, the invention provides immunoglobulin variable domain proteins modified with selected glycans and specific glycan-conjugates thereof. Also provided herein are methods for the production of glycosylated immunoglobulin variable domains and glycan-conjugates thereof.
    Type: Application
    Filed: May 9, 2018
    Publication date: May 14, 2020
    Inventors: Nico Callewaert, Bram Laukens, Loes Van Schie, Wander Van Breedam, Wim Nerinckx